Jury Awards GSK $235 Million after Teva Added Heart Failure Indication to Generic Coreg
A federal jury awarded GlaxoSmithKline $235 million in a suit against Teva, saying the generics manufacturer infringed on GSK’s patent for the cardiovascular drug Coreg when Teva marketed its generic…